Skip to main content
SpringerLink
Log in
Book cover

Acute Leukemias pp 388–391Cite as

Cancer and Leukemia Group B Studies in Relapsed AML

  • Conference paper

  • 79 Accesses

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 34))

Abstract

In the past 20 years, substantial progress has been made in the treatment of acute myeloid leukemia (AML), previously a uniformly fatal diseae. Initial treatment usually consists of a combination of cytosine arabinoside (Ara-C) and daunorubicin, and complete remission (CR) is achieved in approximately 65 % of patients with somewhat higher response rates in younger patients. Once CR is achieved, further chemotherapy is necessary to pro?duce long term disease free survival. How?ever, the majority of patients will relapse; despite the use of these two active drugs as postremission therapy in schedules that have included a 30-fold increase in the dose of Ara-C, there has been, at best, only a modest improvement in survival. Thus, despite 15 year of use of the combination of daunorubicin and Ara-C, the fraction of patients cured with chemotherapy remains in the range 20%–25 % [1–5]. Substantial improvement in long-term disease-free survival has been elusive.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cassileth PA, Begg CB, Silber R, Spiers A, Burkart PT, Scharfman W, Knospe WH, Bennett JM, Mazza JJ, Oken MM, Keller AM, O’Connell MJ (1987) Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 71: 137–140

    PubMed  CAS  Google Scholar 

  2. DutcherJP,Wiernik PH, Markus S,Weinberg V, Schiffer CA, Harwood KV (1989) Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up. Leukemia 2: 413–419

    Google Scholar 

  3. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukemia trial. Lancet II: 1236–1241

    Google Scholar 

  4. Schiffer CA, Mayer RJ for the CALGB (1990) Cancer and Leukemia Group B (CALGB) Studies in acute myeloid leukemia. In: Gale RP (ed) Acute myelogenous leukemia: progress and controversies. Wiley/Liss, New York, pp 313

    Google Scholar 

  5. Wolff SN, Marion J, Stein RS et al. (1985) High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood 65: 1407–1411

    PubMed  CAS  Google Scholar 

  6. Bachur NR, Collins JM, Kelley JA,Van Echo DA, Kaplan RS, Whitacre M (1982) Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics. Clin Pharmacol Ther 31: 650–655

    CAS  Google Scholar 

  7. Van Echo DA, Schulman P, Budman DR, Ferrari A, Wiernik PH (1982) A phase I trial of aziridinylbenzoquinone (NSC 182986) in patients with previously treated acute leukemia. Am J Clin Oncol 5: 405–410

    Article  PubMed  Google Scholar 

  8. Egorin MJ, Fox BM, Spiegel JF, Gutierrez PL, Friedman RD, Bachur NR (1985) Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986). Cancer Res 45: 992–999

    PubMed  CAS  Google Scholar 

  9. Lee EJ, Van Echo DA, Egorin MJ, Nayar B, Shulman P, Schiffer C (1986) Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood 67: 182–187

    PubMed  CAS  Google Scholar 

  10. Schulman P, Davis R, Lee E, Ellerton J, Staszweski H for the Cancer and Leukemia Group B (1987) Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia. Cancer Treat Rep 71: 755–757

    PubMed  CAS  Google Scholar 

  11. Schiffer CA, Davis RB, Mayer RJ, Peterson BA, Lee EJ (1987) Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Cancer Treat Rep 71: 879–880

    PubMed  CAS  Google Scholar 

  12. Lee EJ, Reck K, Schiffer C (1990) Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia. Leukemia 4: 189–192

    PubMed  CAS  Google Scholar 

  13. Paciucci PA, Davis RB, Holland JF et al. (1990) Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol 13: 516–519

    Article  PubMed  CAS  Google Scholar 

  14. Amrein PC, Davis RB, Mayer RJ, Schiffer CA (1990) Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol 35: 80–83

    Article  PubMed  CAS  Google Scholar 

  15. Lee EJ, Paciucci A, Amrein P, Schulman P, Davis R, Schiffer CA (1990) A randomized phase II trial of three regimens in the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults: a CALGB study. Blood 76 [Suppl]: 294a

    Google Scholar 

  16. Brown RA, Herzig RH,Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP (1990) High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473–479

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Maryland Cancer Center, 22 S. Greene St., Baltimore, Maryland, 21201, USA

    E. J. Lee, P. C. Amrein, P. A. Paciucci & C. A. Schiffer

Authors
  1. E. J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. C. Amrein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. A. Paciucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. A. Schiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Straße 33, D-4400, Münster, Federal Republic of Germany

    W. Hiddemann , T. Büchner  & B. Wörmann ,  & 

  2. M. D. Anderson Cancer Center, University of Texas, 1515 Holocombe Boulevard, 77030, Houston, TX, USA

    W. Plunkett , M. Keating  & M. Andreeff ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lee, E.J., Amrein, P.C., Paciucci, P.A., Schiffer, C.A. (1992). Cancer and Leukemia Group B Studies in Relapsed AML. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_62

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76591-9_62

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53949-0

  • Online ISBN: 978-3-642-76591-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation